[
    [
        {
            "time": "",
            "orginal_text": "智通每日大行研报丨中远海控(01919)获美银证券看高至19.25港元 花旗重申吉利汽车(00175)为行业首选",
            "features": {
                "keywords": [
                    "中远海控",
                    "美银证券",
                    "目标价",
                    "19.25港元",
                    "吉利汽车",
                    "花旗",
                    "行业首选"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "航运",
                    "汽车"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "original_text": "智通每日大行研报丨中远海控(01919)获美银证券看高至19.25港元 花旗重申吉利汽车(00175)为行业首选",
            "scores": {
                "News_content": "智通每日大行研报丨中远海控(01919)获美银证券看高至19.25港元 花旗重申吉利汽车(00175)为行业首选",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 7,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "orginal_text": "大摩：予上海医药(02607)“增持”评级 目标价20.5港元",
            "features": {
                "keywords": [
                    "大摩",
                    "上海医药",
                    "增持",
                    "目标价",
                    "20.5港元"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "original_text": "大摩：予上海医药(02607)“增持”评级 目标价20.5港元",
            "scores": {
                "News_content": "大摩：予上海医药(02607)“增持”评级 目标价20.5港元",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 7,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "orginal_text": "九州药业(603456)2021年中报点评：客户储备拐点期、供给能力升级期",
            "features": {
                "keywords": [
                    "九州药业",
                    "2021年中报",
                    "客户储备",
                    "拐点期",
                    "供给能力",
                    "升级期"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "original_text": "九州药业(603456)2021年中报点评：客户储备拐点期、供给能力升级期",
            "scores": {
                "News_content": "九州药业(603456)2021年中报点评：客户储备拐点期、供给能力升级期",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 4
            }
        }
    ]
]